Givinostat will be made available to eligible patients with Duchenne muscular dystrophy after its manufacturer struck a ...

‘Breakthrough’ drug for severe muscle wasting condition set for NHS rollout in England - Givinostat will be made available to ...

Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- - ...

Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development ...

Clair Harris from Slough has been named Fundraiser of the Year at the Muscular Dystrophy UK Stronger Together Awards, held on Monday, April 20 in London and hosted by the charity’s president, Gabby ...

The antics start from midday with amusing categories for all kinds of fur babies, along with trade stands, craft stalls and ...

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...

Start your morning with The National News Desk as Jan Jeffcoat sits down with the President of RMG Research, Scott Rasmussen.

Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the treatment of patients ...